WendySLaneMD

Endocrinology • Asheville, NC

Diabetes, Lipid Metabolism

Endocrinologist, Mountain Diabetes/Endocrine Center

Join to view full profile

Dr. Lane is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Lane's full profile

Already have an account?

Office
141 Asheland Ave
Asheville, NC 28801
Phone+1 828-258-2404

Fax+1 828-258-0864

Education & Training

Maine Medical CenterFellowship, Endocrinology, Diabetes, and Metabolism, 1992 - 1994
Newton-Wellesley HospitalResidency, Internal Medicine, 1984 - 1987
Geisel School of Medicine at DartmouthClass of 1984

Certifications & Licensure

NH State Medical License 1987 - Present
NC State Medical License 1998 - 2025
SC State Medical License 1995 - 1998
ME State Medical License Active through 1994
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Endocrinology, Diabetes and Metabolism

Clinical Trials

U-500R Insulin In Type 2 Diabetes With Severe Insulin Resistance Via Omnipod Start of enrollment: 2007 Dec 01
Completed
Phase 4
Study of Effectiveness of Liraglutide Added to High Dose Insulin in Type II Diabetics Start of enrollment: 2011 Dec 01
Completed
Phase 4
Open-Label Extension Study to Evaluate Long Term Safety and Treatment Effect of DiaPep277® Start of enrollment: 2013 Oct 01
Terminated
Phase 3
An Administration Method Study of Human Regular U-500 Insulin (LY041001) in Participants With Type 2 Diabetes Mellitus Start of enrollment: 2015 Oct 20
Completed
Phase 3
The Efficacy and Safety of Faster Insulin Aspart (Fiasp®) Compared to Conventional Insulin Aspart (NovoLog®) as Correction Bolus Start of enrollment: 2019 Mar 27
Recruiting
Phase 4
Join now to see all

Publications & Presentations

PubMed

31 citations
Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a...
Chantal Mathieu, Björg Ásbjörnsdóttir, Harpreet S Bajaj, Wendy Lane, Ana Laura S A Matos
Lancet. 2023-06-10
1 citations
Effective Overall Glycaemic Control with Fast-Acting Insulin Aspart Across Patients with Different Baseline Characteristics: A Post Hoc Analysis of the Onset 9 Trial.
Wendy Lane, Elena Favaro, Esteban Jódar, Pranav Kelkar, Alejandra Oviedo
Diabetes Therapy. 2022-04-01
3 citations
Basal Insulin degludec and GLycemic control ComparEd to Aspart via insulin Pump in type 1 diabetes (BIGLEAP): a single-center, open-label, randomized, crossover trial.
Wendy Lane, Stephen L. Weinrib, Michael J. Lawrence, Benjamin C. Lane, Ryan T. Jarrett
Endocrine Practice. 2021-11-08

Lectures

Updates in Individualizing Therapy in Type 2 Diabetes: Optimizing Insulin and Non-Insulin Combinations
ENDO 2019 - New Orleans, LA - 3/24/2019
Liraglutide Added to High-Dose Basal/Bolus Insulin in Type 2 Diabetes
Asheville, NC - 6/15/2014

Press Mentions

Paying the Price: Coping with the High Cost of InsulinNovember 26th, 2018